Company Filing History:
Years Active: 2006-2008
Title: Innovations of Bruno Fuks in Neuroscience
Introduction
Bruno Fuks is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of neuroscience, particularly in the study of synaptic vesicle proteins and their role in neurological disorders. With two patents to his name, Fuks is recognized for his innovative approaches to identifying agents that interact with critical binding sites in the brain.
Latest Patents
Fuks' latest patents include methods for identifying agents that bind to a levetiracetam binding site (LBS) or compete with levetiracetam binding to a synaptic vesicle protein 2 (SV2). This invention focuses on characterizing the properties and functions of SV2 proteins. It also includes methods for identifying compounds that modulate the activity of SV2 proteins, particularly in relation to levetiracetam binding. Additionally, his patents provide biotinylated ligands as tools for screening chemical libraries and characterizing SV2 proteins. Another significant patent involves methods for identifying agents for the treatment of seizures, neurological diseases, endocrinopathies, and hormonal diseases, further emphasizing the importance of SV2 proteins in therapeutic applications.
Career Highlights
Bruno Fuks is currently associated with UCB S.A., a global biopharmaceutical company. His work at UCB has allowed him to focus on innovative research that aims to improve the lives of patients suffering from neurological conditions. His contributions to the field have been recognized through his patents and ongoing research efforts.
Collaborations
Fuks has collaborated with notable colleagues, including Berkley Lynch and Karl Nocka. These collaborations have enhanced his research and contributed to the development of innovative solutions in neuroscience.
Conclusion
Bruno Fuks is a prominent inventor whose work in neuroscience has led to significant advancements in understanding and treating neurological disorders. His patents reflect a commitment to innovation and improving patient outcomes in the field.